EN PL
PRACA PRZEGLĄDOWA
Tocilizumab – inhibitor receptora interleukiny 6 – nowa opcja terapeutyczna w leczeniu reumatoidalnego zapalenia stawów
 
Więcej
Ukryj
 
Data publikacji online: 10-06-2009
 
 
Reumatologia 2009;47(2):85-94
 
SŁOWA KLUCZOWE
STRESZCZENIE
Interleukina 6 jest plejotropową cytokiną, która bierze udział w regulacji wrodzonej i nabytej odpowiedzi immunologicznej procesów zapalnych oraz odpowiedzi ostrej fazy. Odgrywa istotną rolę w patogenezie wielu schorzeń zapalnych, wśród nich reumatoidalnego zapalenia stawów. Blokada receptora interleukiny 6 za pomocą przeciwciała monoklonalnego okazała się skuteczną i bezpieczną opcją w terapii tego schorzenia
 
REFERENCJE (17)
1.
Naka T, Nishimoto N, Koshimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4 Suppl 3: S233-S242. .
 
2.
Jones SA, Richards PJ, Scheller J, et al. IL-6 trans-signalling: the in vivo consequences. J Interferon Cytokine Res 2005; 25: 241-253. .
 
3.
Rich RR. Clinical Immunology. 2nd ed. Mosby, Elsevier 2008. .
 
4.
Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8 (Suppl): S3. .
 
5.
Choy E. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl II): ii68-ii69. .
 
6.
Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T (H) 17 cells. Nature 2008; 453: 1051-1057. .
 
7.
Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Current Pharmaceutical Design 2008; 14: 1217-1224. .
 
8.
Robak T, Gladalska A, Stepień H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998; 7: 347-353. .
 
9.
Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-3150. .
 
10.
Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829. .
 
11.
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997. .
 
12.
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980. .
 
13.
Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523. .
 
14.
Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2009. Available at: doi:10.1136/ ard.2008.105197. .
 
15.
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-1167. .
 
16.
Kremer JM, Fleischmann RM, Halland A-M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate response to methotrexate: The LITHE Study. ACR/ARHP Annual Scientific Meeting, San Francisco 24-29 October 2008, Abstract L14 (LITHE). .
 
17.
Charakterystyka Produktu Leczniczego – RoActemra. .
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top